VenatoRx has the potential to receive funding of up to USD 7.4m over five years if all project milestones are met.
VenatoRx's collaborators include leading academicians and scientists from Robert Frederick Smith School of Chemical and Bimolecular Engineering at Cornell University; Broad Institute of MIT and Harvard; Gfree Bio, LLC; and Centro de Química-Física Molecular at the University of Lisbon, Portugal.
The objective of this R01 grant is to provide tools that can facilitate therapeutic discovery for Gram-negative bacterial pathogens, including carbapenem-resistant Enterobacteriaceae, multi-drug resistant Acinetobacter baumannii and/or MDR Pseudomonas aeruginosa.
This initiative will also support VenatoRx's discovery programs targeting novel antibacterial agents.
The project is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI136805.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
VenatoRx is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant bacterial infections and hard-to-treat viral infections.
The company's lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor that directly inhibits all four Ambler classes of beta-lactamases, including the emerging carbapenemases KPC and NDM-1.
In addition, VenatoRx has a broad pipeline of preclinical programmes, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary